Fatemeh Zamani
1,2, Shohreh Almasi
1,2, Tohid Kazemi
1,2, Rana Jahanban Esfahlan
3, Mohammad Reza Aliparasti
4*1 Immunology Research Center (IRC), Tabriz University of Medical Sciences, Tabriz, Iran.
2 Department of Immunology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
3 Department of Medical Biotechnology, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
4 Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Abstract
Type 1
diabetes (T1D) is a pancreatic beta cell specific autoimmune disease. One of the most significant
current discussions in T1D studies is therapy. Since the conventional therapy, islet transplantation and external insulin, e.g., cannot prevent the destructive
autoimmune process against original beta cells and persistent hyperglycemia remains, so recent developments in the field of T1D therapy paved
the way to a renewed interest in immunotherapy based on the disease process, especially monoclonal antibody
therapy. Due to encouraging laboratory results, cytokine antibody-based drugs could
be effective in the clinical direction of the T1D
disease process. Hence, implementation of this approach
can be useful to improve clinical and laboratory manifestations of T1D.